XML 58 R35.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Supplemental Data (unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplemental Data (unaudited) | Supplemental data (unaudited) The following information is presented as supplemental data as required by the indentures governing the Company’s Senior Notes. Condensed Consolidating Statements of Income
For the year ended December 31, 2018 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Dialysis and related lab patient service revenues |  | $ | 10,709,981 |  |  | $ | — |  |  | $ | — |  |  | $ | 10,709,981 |
Less: Provision for uncollectible accounts |  | (49,587 | ) |  | — |  |  | — |  |  | (49,587 | )
Net dialysis and related lab patient service revenues |  | 10,660,394 |  |  | — |  |  | — |  |  | 10,660,394 |
Other revenues |  | 744,457 |  |  | — |  |  | — |  |  | 744,457 |
Total net revenues |  | 11,404,851 |  |  | — |  |  | — |  |  | 11,404,851 |
Operating expenses and charges |  | 9,879,027 |  |  | — |  |  | — |  |  | 9,879,027 |
Operating income |  | 1,525,824 |  |  | — |  |  | — |  |  | 1,525,824 |
Debt expense |  | (487,435 | ) |  | — |  |  | — |  |  | (487,435 | )
Other income, net |  | 10,089 |  |  | — |  |  | — |  |  | 10,089 |
Income tax expense |  | 258,400 |  |  | — |  |  | — |  |  | 258,400 |
Net income from continuing operations |  | 790,078 |  |  | — |  |  | — |  |  | 790,078 |
Net (loss) income from discontinued operations, net of tax |  | (457,038 | ) |  | 37,373 |  |  | 92 |  |  | (494,503 | )
Net income |  | 333,040 |  |  | 37,373 |  |  | 92 |  |  | 295,575 |
Less: Net income attributable to noncontrolling interests |  | (173,646 | ) |  | (7,841 | ) |  | — |  |  | (165,805 | )
Net income attributable to DaVita Inc. |  | $ | 159,394 |  |  | $ | 29,532 |  |  | $ | 92 |  |  | $ | 129,770 |
Condensed Consolidating Statements of Comprehensive Income
For the year ended December 31, 2018 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Net income |  | $ | 333,040 |  |  | $ | 37,373 |  |  | $ | 92 |  |  | $ | 295,575 |
Other comprehensive loss |  | (39,791 | ) |  | — |  |  | — |  |  | (39,791 | )
Total comprehensive income |  | 293,249 |  |  | 37,373 |  |  | 92 |  |  | 255,784 |
Less: Comprehensive income attributable to noncontrolling interest |  | (173,646 | ) |  | (7,841 | ) |  | — |  |  | (165,805 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 119,603 |  |  | $ | 29,532 |  |  | $ | 92 |  |  | $ | 89,979 |
(1) | After the elimination of the unrestricted subsidiaries and the physician groups
Condensed Consolidating Balance Sheets
As of December 31, 2018 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Cash and cash equivalents |  | $ | 323,038 |  |  | $ | — |  |  | $ | — |  |  | $ | 323,038 |
Restricted cash and equivalents |  | 92,382 |  |  | — |  |  | — |  |  | 92,382 |
Accounts receivable, net |  | 1,858,608 |  |  | — |  |  | — |  |  | 1,858,608 |
Other current assets |  | 760,566 |  |  | — |  |  | — |  |  | 760,566 |
Other current assets held for sale |  | 5,389,565 |  |  | 532,050 |  |  | 2,825 |  |  | 4,854,690 |
Total current assets |  | 8,424,159 |  |  | 532,050 |  |  | 2,825 |  |  | 7,889,284 |
Property and equipment, net |  | 3,393,669 |  |  | — |  |  | — |  |  | 3,393,669 |
Amortizable intangibles, net |  | 118,846 |  |  | — |  |  | — |  |  | 118,846 |
Other long-term assets |  | 331,618 |  |  | — |  |  | — |  |  | 331,618 |
Goodwill |  | 6,841,960 |  |  | — |  |  | — |  |  | 6,841,960 |
Total assets |  | $ | 19,110,252 |  |  | $ | 532,050 |  |  | $ | 2,825 |  |  | $ | 18,575,377 |
Current liabilities |  | $ | 3,647,402 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,647,402 |
Current liabilities held for sale |  | 1,243,759 |  |  | 351,925 |  |  | — |  |  | 891,834 |
Total current liabilities |  | 4,891,161 |  |  | 351,925 |  |  | — |  |  | 4,539,236 |
Payables to parent |  | — |  |  | 25,456 |  |  | 2,825 |  |  | (28,281 | )
Long-term debt and other long-term liabilities |  | 9,186,052 |  |  | — |  |  | — |  |  | 9,186,052 |
Noncontrolling interests subject to put provisions |  | 1,124,641 |  |  | — |  |  | — |  |  | 1,124,641 |
Total DaVita Inc. shareholders' equity |  | 3,703,442 |  |  | 154,669 |  |  | — |  |  | 3,548,773 |
Noncontrolling interests not subject to put provisions |  | 204,956 |  |  | — |  |  | — |  |  | 204,956 |
Shareholders' equity |  | 3,908,398 |  |  | 154,669 |  |  | — |  |  | 3,753,729 |
Total liabilities and shareholders' equity |  | $ | 19,110,252 |  |  | $ | 532,050 |  |  | $ | 2,825 |  |  | $ | 18,575,377 |
Condensed Consolidating Statements of Cash Flow
For the year ended December 31, 2018 |  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
Cash flows from operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 333,040 |  |  | $ | 37,373 |  |  | $ | 92 |  |  | $ | 295,575 |
Changes in operating and intercompany assets and liabilities and non-cash items included in net income |  | 1,438,600 |  |  | 81,722 |  |  | (92 | ) |  | 1,356,970 |
Net cash provided by operating activities |  | 1,771,640 |  |  | 119,095 |  |  | — |  |  | 1,652,545 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (987,138 | ) |  | (2,746 | ) |  | — |  |  | (984,392 | )
Acquisitions and divestitures, net |  | (183,156 | ) |  | — |  |  | — |  |  | (183,156 | )
Proceeds from asset sales |  | 150,205 |  |  | — |  |  | — |  |  | 150,205 |
Investments and other items, net |  | 14,446 |  |  | (154 | ) |  | — |  |  | 14,600 |
Net cash used in investing activities |  | (1,005,643 | ) |  | (2,900 | ) |  | — |  |  | (1,002,743 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt and related financing costs, net |  | 694,777 |  |  | — |  |  | — |  |  | 694,777 |
Intercompany |  | — |  |  | 25,296 |  |  | — |  |  | (25,296 | )
Other items |  | (1,320,131 | ) |  | — |  |  | — |  |  | (1,320,131 | )
Net cash (used in) provided by financing activities |  | (625,354 | ) |  | 25,296 |  |  | — |  |  | (650,650 | )
Effect of exchange rate changes on cash |  | (3,350 | ) |  | — |  |  | — |  |  | (3,350 | )
Net increase (decrease) in cash, cash equivalents and restricted cash |  | 137,293 |  |  | 141,491 |  |  | — |  |  | (4,198 | )
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations |  | 240,793 |  |  | 141,491 |  |  | — |  |  | 99,302 |
Net decrease in cash, cash equivalents and restricted cash from continuing operations |  | (103,500 | ) |  | — |  |  | — |  |  | (103,500 | )
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 518,920 |  |  | — |  |  | — |  |  | 518,920 |
Cash, cash equivalents and restricted cash of continuing operations at end of the year |  | $ | 415,420 |  |  | $ | — |  |  | $ | — |  |  | $ | 415,420 |
(1) After the elimination of the unrestricted subsidiaries and the physician groups

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration